https://www.sciencedaily.com/releases/2011/10/111004221110.htm
Taking the new generation anti-inflammatory drug natalizumab for two years lowers the number of remitting multiple sclerosis patients who experience relapses...
multiple sclerosisremittingnatalizumabreducesdisability